Immune system mechanisms -- the work of Dr. Jean-Sébastien Delisle recognized

November 29, 2016

The recent work of Dr. Jean-Sebastien Delisle of the Maisonneuve-Rosemont Hospital Research Center (CIUSSS-EMTL) affiliated with the University of Montreal, which uncovers novel immune system mechanisms, has been recognized by the highly respected Journal of Immunology. Indeed, the official journal of the American Association of Immunologists has ranked Dr. Delisle's article published in its November 15 issue among the top 10% of its best scientific articles.

An important step towards understanding immunity

The research of Dr. Delisle and his team has identified the unexpected role of Neuropilin-1, a membrane receptor, and the phenomenon of dendritic cell maturation, which is an essential link in the immune response to infection and disease. The scope of this work is considerable because it involves identifying a new target for optimizing immune responses for a large number of diseases.

Dr. Delisle's discovery is timely and will help improve the way the immune system is used to treat cancer, said Dr. Denis-Claude Roy, scientific director of the Centre de recherche Hopital Maisonneuve-Rosemont. By targeting this mechanism, we can eventually consider the possibility of improving the responses in conditions unfavourable to the immune system, especially with respect to many cancers, added Dr. Delisle.

It is not the first time Dr. Delisle's research has been recognized. Recently, his Phase 1 clinical study EBV-TCL-01, using laboratory-manipulated cells as an innovative treatment for Epstein-Barr virus-associated lymphomas, received approval from Health Canada, a first for the country.

The excellence of the Maisonneuve-Rosemont Hospital Research Centre

Dr. Delisle's team is among the leading researchers at Maisonneuve-Rosemont Hospital, its Research Centre, and its Centre of Excellence in Cell Therapy, who are working to develop the therapies of tomorrow for a large number of diseases, from cancer to pathologies of the immune system.

University of Montreal

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to